202 related articles for article (PubMed ID: 31757465)
21. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection.
Zhang A; Månér S; Betz R; Angström T; Stendahl U; Bergman F; Zetterberg A; Wallin KL
Int J Cancer; 2002 Oct; 101(5):427-33. PubMed ID: 12216070
[TBL] [Abstract][Full Text] [Related]
22. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases.
Stenzel A; Semczuk A; Rózyńskal K; Jakowicki J; Wojcierowski J
Pathol Res Pract; 2001; 197(9):597-603. PubMed ID: 11569923
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer.
Morgan EL; Patterson MR; Ryder EL; Lee SY; Wasson CW; Harper KL; Li Y; Griffin S; Blair GE; Whitehouse A; Macdonald A
PLoS Pathog; 2020 Jun; 16(6):e1008624. PubMed ID: 32555725
[TBL] [Abstract][Full Text] [Related]
24. Over-expression of topoisomerase IIalpha is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment.
Branca M; Giorgi C; Ciotti M; Santini D; Di Bonito L; Costa S; Benedetto A; Bonifacio D; Di Bonito P; Paba P; Accardi L; Mariani L; Ruutu M; Syrjänen SM; Favalli C; Syrjänen K;
Int J Gynecol Pathol; 2006 Oct; 25(4):383-92. PubMed ID: 16990717
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
Jiang W; Xiang L; Pei X; He T; Shen X; Wu X; Yang H
J Gynecol Oncol; 2018 Jan; 29(1):e4. PubMed ID: 29185262
[TBL] [Abstract][Full Text] [Related]
26. EGFR Promoter Methylation, EGFR Mutation, and HPV Infection in Chinese Cervical Squamous Cell Carcinoma.
Zhang W; Jiang Y; Yu Q; Qiang S; Liang P; Gao Y; Zhao X; Liu W; Zhang J
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):661-6. PubMed ID: 25789535
[TBL] [Abstract][Full Text] [Related]
27. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
28. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - a systematic review and meta-analysis.
Thomas LK; Bermejo JL; Vinokurova S; Jensen K; Bierkens M; Steenbergen R; Bergmann M; von Knebel Doeberitz M; Reuschenbach M
Eur J Cancer; 2014 Jan; 50(1):85-98. PubMed ID: 24054023
[TBL] [Abstract][Full Text] [Related]
29. Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.
Chakravarthy A; Reddin I; Henderson S; Dong C; Kirkwood N; Jeyakumar M; Rodriguez DR; Martinez NG; McDermott J; Su X; Egawa N; Fjeldbo CS; Skingen VE; Lyng H; Halle MK; Krakstad C; Soleiman A; Sprung S; Lechner M; Ellis PJI; Wass M; Michaelis M; Fiegl H; Salvesen H; Thomas GJ; Doorbar J; Chester K; Feber A; Fenton TR
Nat Commun; 2022 Oct; 13(1):5818. PubMed ID: 36207323
[TBL] [Abstract][Full Text] [Related]
30. Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas.
Ramberg I; Vieira FG; Toft PB; von Buchwald C; Funding M; Nielsen FC; Heegaard S
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):11. PubMed ID: 34779821
[TBL] [Abstract][Full Text] [Related]
31. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa.
Denny L; Adewole I; Anorlu R; Dreyer G; Moodley M; Smith T; Snyman L; Wiredu E; Molijn A; Quint W; Ramakrishnan G; Schmidt J
Int J Cancer; 2014 Mar; 134(6):1389-98. PubMed ID: 23929250
[TBL] [Abstract][Full Text] [Related]
34. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer.
Burger RA; Monk BJ; Kurosaki T; Anton-Culver H; Vasilev SA; Berman ML; Wilczynski SP
J Natl Cancer Inst; 1996 Oct; 88(19):1361-8. PubMed ID: 8827013
[TBL] [Abstract][Full Text] [Related]
35. Comparative molecular profiling of HPV-induced squamous cell carcinomas.
Koncar RF; Feldman R; Bahassi EM; Hashemi Sadraei N
Cancer Med; 2017 Jul; 6(7):1673-1685. PubMed ID: 28556593
[TBL] [Abstract][Full Text] [Related]
36. A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer.
Huang Y; He Q; Xu K; Zhou J; Yin J; Li F; Feng M; Lang J
Int J Gynecol Cancer; 2019 Mar; 29(3):459-465. PubMed ID: 30733276
[TBL] [Abstract][Full Text] [Related]
37. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.
Rodríguez-Carunchio L; Soveral I; Steenbergen RD; Torné A; Martinez S; Fusté P; Pahisa J; Marimon L; Ordi J; del Pino M
BJOG; 2015 Jan; 122(1):119-27. PubMed ID: 25229645
[TBL] [Abstract][Full Text] [Related]
38. Reduction in the copy number and expression level of the recurrent human papillomavirus integration gene fragile histidine triad (FHIT) predicts the transition of cervical lesions.
Wang L; Shen H; Feng B; Zhu D; Yu L; Tian X; Ren C; Gao C; Li X; Ma D; Hu Z; Wang H
PLoS One; 2017; 12(4):e0175520. PubMed ID: 28414756
[TBL] [Abstract][Full Text] [Related]
39. Global Variation of Human Papillomavirus Genotypes and Selected Genes Involved in Cervical Malignancies.
Husain RS; Ramakrishnan V
Ann Glob Health; 2015; 81(5):675-83. PubMed ID: 27036725
[TBL] [Abstract][Full Text] [Related]
40. Clinical Role of the Detection of Human Telomerase RNA Component Gene Amplification by Fluorescence in situ Hybridization on Liquid-Based Cervical Samples: Comparison with Human Papillomavirus-DNA Testing and Histopathology.
Zappacosta R; Ianieri MM; Buca D; Repetti E; Ricciardulli A; Liberati M
Acta Cytol; 2015; 59(4):345-54. PubMed ID: 26343271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
